GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
A phase 2 trial of GKL-006 Injection in hepatocellular carcinoma, run by Beijing Gene Key Life Technology Co., Ltd, now recruiting.
Overview
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT07209813 by Beijing Gene Key Life Technology Co., Ltd, with 48 participants planned, started 2025-11-14 and due to reach its primary completion in 2027-09-30. Interventions recorded: GKL-006 Injection and TACE.
Similar pages
not linked directly; found by shared links- TrialA Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer
Shares Beijing Gene Key Life Technology and the tag pipeline.
- TrialA Study of PTX-9908 Injection for Non-resectable HCC with TACE
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialGPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialEfficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialTo Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialA Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
Shares Hepatocellular carcinoma and the tag pipeline.